"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...
Ophthalmic solutions of NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) hydrochloride are contraindicated in persons with narrow angle glaucoma (and in those individuals who are hypersensitive to NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) ). NEO-SYNEPHRINE (phenylephrine hydrochloride ophthalmic solution) hydrochloride 10 percent ophthalmic solutions are contraindicated in infants and in patients with aneurysms.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/6/2008
Additional Neo-Synephrine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.